Insmed Inc (INSM)vsModerna Inc (MRNA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
MRNA
Moderna Inc
$53.54
+4.29%
HEALTHCARE · Cap: $21.23B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 221% more annual revenue ($1.94B vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -145.2%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
MRNA
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Weak financial health signals
ROE of -28.9% — below average capital efficiency
Revenue declined 29.8%
Earnings declined 85.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MRNA
The strongest argument for MRNA centers on Altman Z-Score, Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : MRNA
The primary concerns for MRNA are Piotroski F-Score, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
MRNA carries more volatility with a beta of 1.35 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
MRNA generates stronger free cash flow (912M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?